Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Assess the Efficacy, Safety, and Tolerability of Abstral Oral Disintegrating Tablet (ODT) for the Management of Breakthrough Cancer Pain in Korean Cancer Patients

NCT03895762 is registered in ClinicalTrials.gov with A.Menarini Asia-Pacific Holdings Pte Ltd as lead sponsor.

NCT NCT03895762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03895762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Assess the Efficacy, Safety, and Tolerability of Abstral Oral Disintegrating Tablet (ODT) for the Management of Breakthrough Cancer Pain in Korean Cancer Patients
Lead sponsor
A.Menarini Asia-Pacific Holdings Pte Ltd
Phase
Observational
Overall status
Completed
Start date
July 4, 2017
Completion date
June 28, 2019
Enrollment
143 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breakthrough cancer pain